Navigation Links
Publication Addresses Misconceptions About Emergency Contraception
Date:3/27/2008

MONTVALE, N.J., March 27 /PRNewswire/ -- The approval of an emergency contraceptive with over-the-counter access for individuals aged 18 years and older provides another option for preventing unintended pregnancy. However, many patients are uninformed or misinformed about how emergency contraception works and when they may need it. Clinicians should to be able to address these questions and proactively counsel patients about their risk of pregnancy.

To address this issue, OBG Management and The Journal of Family Practice have collaborated to publish "Emergency contraception: When and how to use it," distributed as a supplement to the February 2008 issues.

This publication provides clinicians with valuable information about emergency contraception. A handout sheet for patients was included to reinforce clinical counseling efforts. The publication highlights effective strategies for collaboration between clinicians and pharmacists to promote access to emergency contraception.

Supplement co-author Joseph S. Sanfilippo, MD, MBA, remarked on the relevance of this material, in light of the recent report from the CDC that shows an increased incidence of teen pregnancy: "Emergency contraception will avert the problems intrinsic to conception in this age group. Studies show that teen education about Plan B is not associated with any increase in incidence of teen sexual activity."

OBG Management, a peer-reviewed journal distributed to 40,000 ob/gyns, and The Journal of Family Practice, a peer-reviewed journal distributed to 96,000 primary care physicians, have developed this supplement under a grant from Duramed Pharmaceuticals, Inc.

Physicians can access this supplement on http://www.obgmanagement.com and on http://www.jfponline.com. Nurse practitioners and physician assistants can find this publication at

SOURCE The Journal of Family Practice; OBG Management
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Oncolytics Biotech Inc. Announces Publication of Research on Immune Response to REOLYSIN(R) during a Phase I Clinical Trial
2. Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
3. Ortho Biotech Statement On JAMA Publication Regarding Erythropoiesis-Stimulating Agents
4. Oncolytics Biotech Inc. Announces Publication of Research on Combination Reovirus and Radiation Therapy
5. BioTrends Releases Fourth Annual Nephrology TreatmentTrends Publication Highlighting Market Trends for Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism
6. Oncolytics Biotech Inc. Announces Publication of Research on Combination Reovirus and Cyclophosphamide Treatment
7. Research by Case Western Reserve University, VA earns cover of prestigious science publication
8. Kendle Named Best CRO for Second Consecutive Year by Leading Global Pharmaceutical Publication Scrip
9. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
10. Industry Executives Finding Value in Shift of Scientific Publications
11. Amarin Announces Publication of Pre-Clinical Memory Data in Journal of Neurochemistry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)...  Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a leading ... today announced that executives from the company will present ... , Pedro Lichtinger , Chief ... Annual Global Investment Conference on Wednesday, September 10, 2015 ... in New York City . ...
(Date:8/27/2015)... Boston, MA (PRWEB) , ... August 27, 2015 , ... ... the United States, ranking iLab Solutions as number 1,361 in growth for the three ... part of the top 0.1% fastest-growing privately held organizations in the country. , ...
(Date:8/26/2015)... KS (PRWEB) , ... August 26, 2015 , ... ... Biologic Solutions, announces today that a second US laboratory is to open in ... accordance with the continued partnership and long-term growth of research and development through ...
(Date:8/26/2015)... , Aug. 26, 2015  The Diabetes ... the University of Miami Miller School of Medicine, ... clinical trial to test for the first time ... successfully completed.  This FDA approved Phase I/II study ... transplantation and is an important first step toward ...
Breaking Biology Technology:Asterias Biotherapeutics to Present at Upcoming Investor Conferences 2iLab Solutions Named to 2015 Inc. 5000 List 2iLab Solutions Named to 2015 Inc. 5000 List 3MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas 2MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas 3Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 2Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 3Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 4
... Accelerating Your Research with the BD FACSCanto , ... . , Introduction ... Sampler (HTS) provides fully automated and rapid sample acquisition. It is designed to ... 1% or less. The BD HTS adapts to the BD FACSCanto ...
... Jason S. Wood, Varian, Inc. , ... Cytochrome P450s (CYPs) are heme-containing enzymes responsible for ... are part of the Phase I (oxidative) metabolism within the body, ... easy elimination of the drug or further conjugation by Phase II ...
... D. Garteiz, R. Morrow, and B. Alexander, TexMS Analytical Services, Houston, TX ... Inc., Walnut Creek, CA , ... that make up the pigments in fruits, vegetables, and herbs. There have ... number of serious illnesses, such as rheumatoid arthritis, cancer, cataracts, anxiety, and ...
Cached Biology Technology:Technical Specifications, Accelerating Your Research with the BD FACSCanto, High Throughput Sampler Option 2Technical Specifications, Accelerating Your Research with the BD FACSCanto, High Throughput Sampler Option 3Simultaneous Detection of CYP3A4, CYP2D6 and CYP2C9 Metabolites with a Single, Sensitive, LC/MS/MS Method 2Simultaneous Detection of CYP3A4, CYP2D6 and CYP2C9 Metabolites with a Single, Sensitive, LC/MS/MS Method 3Quantitation of a Dinitro Flavonoid (DNF) in Rat Plasma Using the Varian 1200L LC/MS/MS System 2Quantitation of a Dinitro Flavonoid (DNF) in Rat Plasma Using the Varian 1200L LC/MS/MS System 3
(Date:8/11/2015)... -- Today, ZUK announced its Android smartphone Z1, featuring ... revenues in 2015 that relate to sales of FPC1155 for this ... 2,200 MSEK for 2015. Jörgen Lantto, CEO of FPC, ... smartphone manufacturer in China and we ... 155 for Z1 , ...
(Date:8/6/2015)... JOSE, Calif. , Aug. 6, 2015 /PRNewswire/ ... leading developer of human interface solutions, today announced ... TouchPad technologies on Windows 10. Microsoft leveraged Synaptics, ... to the operating system. Through ... drivers are fully certified with Microsoft,s Precision TouchPad ...
(Date:8/4/2015)... N.Y., Aug. 4, 2015  AMRI (NASDAQ: AMRI ) today ... 30, 2015. Highlights: , Second quarter contract ... from 2014 , Adjusted contract margins of ... of $0.22, including a $0.05 decrease in EPS from royalties in ... $16 million "We are very pleased to present ...
Breaking Biology News(10 mins):FPC's Touch Fingerprint Sensor FPC1155 in ZUK's Smartphone Z1 2Synaptics Chosen for Human Interface Co-Development on Windows 10 2AMRI Announces Second Quarter 2015 Results 2AMRI Announces Second Quarter 2015 Results 3AMRI Announces Second Quarter 2015 Results 4AMRI Announces Second Quarter 2015 Results 5AMRI Announces Second Quarter 2015 Results 6AMRI Announces Second Quarter 2015 Results 7AMRI Announces Second Quarter 2015 Results 8AMRI Announces Second Quarter 2015 Results 9AMRI Announces Second Quarter 2015 Results 10AMRI Announces Second Quarter 2015 Results 11AMRI Announces Second Quarter 2015 Results 12AMRI Announces Second Quarter 2015 Results 13AMRI Announces Second Quarter 2015 Results 14AMRI Announces Second Quarter 2015 Results 15AMRI Announces Second Quarter 2015 Results 16AMRI Announces Second Quarter 2015 Results 17AMRI Announces Second Quarter 2015 Results 18AMRI Announces Second Quarter 2015 Results 19AMRI Announces Second Quarter 2015 Results 20AMRI Announces Second Quarter 2015 Results 21AMRI Announces Second Quarter 2015 Results 22AMRI Announces Second Quarter 2015 Results 23AMRI Announces Second Quarter 2015 Results 24
... live longer and experience delays in disease progression when a ... added to treatment with erlotinib, the results of a double-blind ... lung cancer research for the Sarah Cannon Research Institute in ... of the European Society for Medical Oncology (ESMO) in Milan, ...
... pregnancy with twins is about 40%. Women with multiple ... the term of their pregnancy. Joachim W Dudenhausen from ... from Magdeburg University Medical Center, investigate which risks can ... Arztebl Int 2010; 107[38]: 663-8). 14 in 1000 ...
... professor has received a U.S. Department of Agriculture grant ... adolescence. Rusty Tchernis, an associate professor of ... received a $225,000 grant to study the "Dynamics of ... University. Tchernis said, the research will explore whether ...
Cached Biology News:New targeted therapy adds benefit to erlotinib in some patients with advanced lung cancer 2
2,4,6, Trinitrophenyl hapten is conjugated to lipopolysaccharide (LPS)....
For the quantitative determination of cyclic AMP (cAMP) concentrations in cell culture supernates, serum, plasma, saliva, urine and cell lysates....
... the Flp-In System creates isogenic cell ... levels of the protein of interest. ... Figure 3 (click link below). In ... chloramphenicol-acetyl transferase (CAT) was subcloned into ...
... solvents can be used, such as water, benzene, formamide, nitrobenzene, cyclohexane, 1,4-dioxane, p-xylene, dimethyl sulfoxide, freon ... * Range: 12-position switchable: ... ... ...
Biology Products: